Literature DB >> 14693746

Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast.

Ashraful Hoque1, Jennifer Carter, Weiya Xia, Mien-Chie Hung, Aysegul A Sahin, Subrata Sen, Scott M Lippman.   

Abstract

The biological mechanisms involved in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer are not fully understood. We previously have shown that the putative oncogene Aurora-A/STK15/BTAK, encoding a centrosome-associated kinase that regulates centrosomes and chromosome segregation, is amplified in human breast cancer. In this study, 37 archival breast tissue specimens of histologically confirmed DCIS lesions with adjacent invasive carcinoma and morphologically nonmalignant mammary ducts were analyzed immunohistochemically for expression of STK15. Statistically significant differences in overexpression of STK15 was found between invasive cancer and either nonmalignant mammary ducts (P < 0.0001) or DCIS lesions (P < 0.0005). Abnormalities in centrosome size and number was detected in the samples analyzed and 56% (14 of 25) of the cases also showed aneuploidy reflected in >2 signals of chromosome 3 and 17. Our data demonstrate that STK15 overexpression correlates with centrosome anomaly and aneuploidy in DCIS, and loss of STK15 overexpression is associated with progression of in situ to ductal invasive breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14693746

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  25 in total

1.  Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.

Authors:  Norman L Lehman; James P O'Donnell; Lisa J Whiteley; Robert T Stapp; Trang D Lehman; Kathleen M Roszka; Lonni R Schultz; Caitlin J Williams; Tom Mikkelsen; Stephen L Brown; Jeffrey A Ecsedy; Laila M Poisson
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

2.  A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma In Situ.

Authors:  Michael S Toss; Guanhao Wei; Jaspreet Kaur; Karuna Mittal; Da Hoon Choi; Brian D Melton; Remus M Osan; Islam M Miligy; Andrew R Green; Emiel A M Janssen; Håvard Søiland; Keerthi Gogineni; Upender Manne; Padmashree Rida; Emad A Rakha; Ritu Aneja
Journal:  Clin Cancer Res       Date:  2020-01-14       Impact factor: 12.531

3.  Estrogen-induced aurora kinase-A (AURKA) gene expression is activated by GATA-3 in estrogen receptor-positive breast cancer cells.

Authors:  Shoulei Jiang; Hiroshi Katayama; Jin Wang; Sara Antonia Li; Yan Hong; Laszlo Radvanyi; Jonathan J Li; Subrata Sen
Journal:  Horm Cancer       Date:  2010-02-20       Impact factor: 3.869

4.  Conditional transgenic system for mouse aurora a kinase: degradation by the ubiquitin proteasome pathway controls the level of the transgenic protein.

Authors:  Tomokazu Fukuda; Yuji Mishina; Michael P Walker; Richard P DiAugustine
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

5.  Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.

Authors:  John McLaughlin; Vadim Markovtsov; Hui Li; Steve Wong; Marina Gelman; Yanhong Zhu; Christian Franci; D Wayne Lang; Erlina Pali; Joe Lasaga; Caroline Low; Feifei Zhao; Betty Chang; Tarikere L Gururaja; Weiduan Xu; Muhammad Baluom; David Sweeny; David Carroll; Arvinder Sran; Sambaiah Thota; Manjeet Parmer; Angela Romane; George Clemens; Elliott Grossbard; Kunbin Qu; Yonchu Jenkins; Taisei Kinoshita; Vanessa Taylor; Sacha J Holland; Ankush Argade; Rajinder Singh; Polly Pine; Donald G Payan; Yasumichi Hitoshi
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

6.  Spindle proteins are differentially expressed in the various histological subtypes of testicular germ cell tumors.

Authors:  Espen Burum-Auensen; Rolf I Skotheim; Aasa R Schjølberg; Jo Røislien; Ragnhild A Lothe; Ole Petter F Clausen
Journal:  J Carcinog       Date:  2010-03-04

7.  Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate.

Authors:  Noa Matarasso; Anat Bar-Shira; Uri Rozovski; Serena Rosner; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2007-09       Impact factor: 5.715

8.  Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer.

Authors:  Yasmine Nadler; Robert L Camp; Candice Schwartz; David L Rimm; Harriet M Kluger; Yuval Kluger
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

9.  Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.

Authors:  Gerald Falchook; Razelle Kurzrock; Launce Gouw; David Hong; Kimberly A McGregor; Xiaofei Zhou; Hongliang Shi; Howard Fingert; Sunil Sharma
Journal:  Invest New Drugs       Date:  2014-06-01       Impact factor: 3.850

10.  Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

Authors:  Gerald Falchook; Robert L Coleman; Andrzej Roszak; Kian Behbakht; Ursula Matulonis; Isabelle Ray-Coquard; Piotr Sawrycki; Linda R Duska; William Tew; Sharad Ghamande; Anne Lesoin; Peter E Schwartz; Joseph Buscema; Michel Fabbro; Alain Lortholary; Barbara Goff; Razelle Kurzrock; Lainie P Martin; Heidi J Gray; Siqing Fu; Emily Sheldon-Waniga; Huamao Mark Lin; Karthik Venkatakrishnan; Xiaofei Zhou; E Jane Leonard; Russell J Schilder
Journal:  JAMA Oncol       Date:  2019-01-10       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.